[ad_1] Reuters The Swiss drug manufacturer Novartis has agreed to buy the US endocyte cancer treatment provider for $ 2.1 billion. Under this agreement, Novartis will pay $ 24 per share in …
Read More »Endocyte anticancer drug provider increases 50% after Novartis agrees to buy it for $ 2.1 billion (ECYT, NVS)
